Atrial fibrillation and hyperthyroidism: choosing control strategy

Atrial fibrillation can be the first cardiovascular sign of hyperthyroidism, particularly in older adults whose thyroid symptoms are subtle. Excess thyroid hormone increases sympathetic activity, shortens atrial refractory periods and heightens myocardial sensitivity to catecholamines. The result may be a rapid, irregular ventricular response, palpitations, exercise intolerance, chest discomfort or heart failure.

Management requires two decisions that are closely related but not identical: how to slow the ventricular rate and whether to restore sinus rhythm. In many patients, treating thyrotoxicosis allows atrial fibrillation to settle without immediate cardioversion. Others need urgent rhythm intervention because of haemodynamic compromise, persistent symptoms or a high risk of tachycardia-mediated cardiomyopathy.

Why thyroid excess triggers atrial fibrillation

Hyperthyroidism changes the electrophysiological environment of the atria. Increased adrenergic tone promotes triggered activity, while altered conduction and atrial remodelling make multiple re-entry wavelets more likely. This helps explain why atrial fibrillation is common in thyrotoxicosis and why a rapid ventricular rate may be difficult to tolerate in people with limited diastolic filling or pre-existing coronary disease.

The cause may be Graves’ disease, toxic multinodular goitre, toxic adenoma, thyroiditis or excessive thyroid hormone replacement. A careful history should cover weight loss, tremor, heat intolerance, diarrhoea, anxiety, neck symptoms and recent changes in levothyroxine or complementary medicines. Examination and testing generally include thyroid-stimulating hormone, free thyroxine and, when indicated, free triiodothyronine, alongside electrolytes, renal function, a full blood count and an electrocardiogram.

The immediate clinical priority is to identify the severity of the thyrotoxic state. Fever, delirium, vomiting, severe tachycardia, hypotension or acute heart failure may indicate thyroid storm, which needs emergency treatment rather than a routine outpatient rate-control plan. In Australia, a patient presenting to an emergency department in Sydney, Melbourne or any regional centre with instability should be assessed for both arrhythmia complications and the underlying endocrine emergency.

Rate control while thyroid disease is treated

A beta blocker is usually the preferred initial treatment when there is no significant contraindication. Propranolol has the additional benefit of reducing peripheral conversion of thyroxine to triiodothyronine at adequate doses, although the main practical objective is ventricular rate reduction and symptom relief. Metoprolol and other cardioselective agents may be useful where bronchospasm risk, dosing convenience or local prescribing practice makes them preferable.

Rate control should be individualised rather than driven by a single numerical target. Resting and exertional heart rate, blood pressure, symptoms, left ventricular function and coexisting disease all matter. Caution is required in acute decompensated heart failure, severe asthma, marked conduction disease and hypotension. A cautious, supervised approach is particularly important when the patient has been tachycardic for an uncertain duration.

Diltiazem or verapamil can be considered when beta blockers are unsuitable, provided left ventricular systolic function is preserved and there is no significant hypotension or pre-excitation. Digoxin may provide additional control in selected patients with heart failure or limited blood pressure reserve, but its effect is less reliable in a high-adrenergic state. Serum levels, renal function and drug interactions need attention, especially in older Australians receiving multiple medicines through the Pharmaceutical Benefits Scheme.

Rate control is often a bridge rather than the whole treatment. Antithyroid therapy, management of thyroiditis where appropriate, and review of exogenous hormone are what remove the precipitating stimulus. A plan should include repeat thyroid tests and reassessment after euthyroidism, because the dose of a beta blocker or other rate-limiting medicine may need to fall as adrenergic drive subsides.

When rhythm control becomes the priority

Urgent synchronised electrical cardioversion is appropriate when atrial fibrillation causes haemodynamic instability, ongoing myocardial ischaemia, pulmonary oedema or severe symptoms that do not respond to initial treatment. Thyrotoxicosis does not remove the need to stabilise the circulation first. Sedation, anticoagulation assessment and management of the thyroid crisis should occur in parallel.

For a stable patient, spontaneous conversion to sinus rhythm is common after thyroid function begins to normalise. This supports an initial period of rate control and endocrine treatment when symptoms are tolerable and there is no major structural heart disease. Persistent atrial fibrillation, recurrent episodes, worsening ventricular function or unacceptable symptoms may justify cardioversion after an appropriate anticoagulation strategy has been established.

The timing of cardioversion depends on the duration of atrial fibrillation and certainty about onset. If the episode has lasted more than 48 hours or its duration is unclear, clinicians generally use therapeutic anticoagulation before cardioversion or a transoesophageal echocardiographic strategy to exclude atrial thrombus. Anticoagulation is then continued afterwards according to thromboembolic risk, even if sinus rhythm is restored.

Antiarrhythmic drug selection requires special care. Amiodarone can slow the rate and restore rhythm, but its iodine content and thyroid toxicity make it problematic in patients with active thyroid disease unless the clinical situation warrants it and specialist oversight is available. Flecainide or propafenone may be options in carefully selected patients without significant structural or ischaemic heart disease. A cardiologist or electrophysiologist should guide treatment when rhythm control is being considered.

Stroke prevention and safety considerations

The presence of hyperthyroidism can make atrial fibrillation seem temporary, but a transient trigger does not automatically mean low embolic risk. Australian practice commonly uses the CHA₂DS₂-VA framework, considering congestive heart failure, hypertension, age, diabetes, previous stroke or transient ischaemic attack, and vascular disease. Age and comorbidity remain central even when thyroid function is expected to improve.

Anticoagulation decisions should incorporate bleeding risk, kidney function, falls, concurrent medicines and the likely duration of atrial fibrillation. Direct oral anticoagulants are widely used in Australia when clinically suitable, while warfarin remains important in particular situations such as mechanical heart valves or selected valvular disease. PBS eligibility, dose requirements and monitoring access should be checked rather than assumed, especially for people moving between metropolitan and rural services.

Aspirin is not an equivalent substitute for anticoagulation in patients who require stroke prevention for atrial fibrillation. The decision should also be revisited after euthyroidism, because the arrhythmia may recur silently or persist due to atrial enlargement, hypertension, sleep apnoea or underlying cardiomyopathy. Ambulatory monitoring can help distinguish genuine resolution from intermittent episodes.

Drug safety extends beyond anticoagulants and thyroid medicines. Electrolyte abnormalities, renal impairment and QT-prolonging combinations can increase proarrhythmic risk. Patients with syncope, a family history of sudden death or unexplained ventricular arrhythmia need a broader inherited arrhythmia assessment; a useful electrophysiology resource on genotype–phenotype correlations illustrates why clinical history and genetic information must be interpreted together.

Follow-up after thyroid function normalises

A rhythm decision should be reviewed rather than treated as permanent. Thyroid-stimulating hormone can remain suppressed after free thyroid hormone levels improve, and symptoms may not track laboratory results perfectly. Follow-up should assess resting and exertional rate, rhythm, ventricular function, thyroid results, medication tolerance and the need for ongoing anticoagulation.

If atrial fibrillation persists despite restored thyroid function, the patient should be managed according to the usual principles for non-valvular atrial fibrillation. Echocardiography can identify atrial enlargement, valve disease and reduced ejection fraction. Sleep apnoea, obesity, alcohol intake and hypertension deserve attention because they can maintain the arrhythmogenic substrate after the initial endocrine trigger has disappeared.

Catheter ablation may be considered for symptomatic recurrent atrial fibrillation, particularly when antiarrhythmic medication is ineffective, poorly tolerated or unsuitable. It is not a substitute for treating hyperthyroidism, and proceeding before the endocrine condition is controlled may complicate interpretation of recurrence. A rhythm specialist can help determine whether the patient is experiencing an isolated thyrotoxic episode or has entered a longer-term atrial fibrillation pathway.

Device therapy is not routine for uncomplicated atrial fibrillation, but complex patients may have broader electrophysiological issues. For clinicians managing inherited disease, ventricular arrhythmia or implantable cardioverter-defibrillators, the discussion of defibrillation threshold testing provides relevant context about procedural decision-making and device safety.

Australian care also needs to account for geography and continuity. A patient in Perth, Brisbane or Adelaide may have timely access to electrophysiology services, while someone in rural Queensland, Western Australia or the Northern Territory may require shared care, telehealth and coordinated pathology. Clear written instructions about beta-blocker dosing, anticoagulation, warning symptoms and thyroid follow-up help reduce gaps between general practice, emergency care and specialist review.

Current research and clinical guidance continue to refine the balance between ventricular rate control, early rhythm restoration and long-term risk reduction. Clinicians and trainees can explore the journal’s arrhythmia collections for peer-reviewed work on atrial fibrillation, ablation, pacing, implantable devices and related pharmacology.

For patients, the practical message is to treat the thyroid disorder promptly, control the ventricular response safely, assess stroke risk independently and reassess rhythm once euthyroidism is achieved. For clinicians, documenting the onset and severity of atrial fibrillation, thyroid status, anticoagulation reasoning and follow-up plan creates a safer pathway from acute presentation to durable rhythm care. Consult the Journal of Arrhythmia’s research and educational resources to support evidence-based decisions in this evolving area.